NCT07894328
A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Timeframe: Up to approximately 4 years
Secondary (7)
Overall Survival (OS)
Progression Free Survival (PFS) by Investigator
Second progression-free survival (PFS2)
Overall Response Rate (ORR)
Clinical Benefit Rate (CBR)
Show 2 moreShow less
Duration of Response (DOR)
Incidence of treatment emergent treatment related adverse events/serious adverse events
Arms and interventions
Arm A: HRS-6209 + LetrozoleExperimental
Arm B: CDK4/6 inhibitors+ Aromatase InhibitorActive comparator
Drugs: HRS-6209 + Letrozole, Dalpciclib/Palbociclib + Letrozole/Anastrozole
Sites
1 site in 1 country
- Tianjin Medical University Cancer Institute & HospitalTianjin, Tianjin Municipality, China